Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8852W HIGH $17.25
Volume
3.58 K
Value Traded
2.17 M
Short % Float
9.54%
Days to Cover
11.9
-9.74%Week
-36.5%1 Month
-26.48%3 Month
-36.21%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
621.44 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
414.40 M
Total Shares
64.40 M
Float Shares
53.36 M
Insiders
9.15%
Institutions
36.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ANL Catalyst Timeline
Dated clinical, regulatory and corporate events for Adlai Nortye Ltd. American Depositary Shares
Catalyst Timeline
Dated clinical, regulatory & corporate events for Adlai Nortye Ltd. American Depositary Shares
31Total events
9Upcoming
7Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 16
▲Partnership / LicenseAN4035Corporate
Adlai Nortye enters CTCSAs with Lilly and Merck KGaA for cetuximab supply in AN4035 Phase I
CEACAM5-enriched RAS-addicted solid tumorssource ↗
●Management ChangeCorporate
Adlai Nortye appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
▲First Patient DosedAN4035Trial
First patient dosed with AN4035 in Australia, initiating global Phase I trial
CEACAM5-enriched RAS-addicted solid tumorssource ↗
▲IND ClearanceAN4035IND
U.S. FDA cleared IND for AN4035 with Study-May-Proceed letter
CEACAM5-enriched RAS-addicted solid tumorssource ↗
▲Trial InitiationAN4035Trial
Global Phase I trial of AN4035 initiated
CEACAM5-enriched RAS-addicted solid tumorssource ↗
▲Trial InitiationAN4035Trial
CTN submitted to TGA and HREC approval received for Phase I trial of AN4035
CEACAM5-enriched RAS-addicted solid tumorssource ↗
▲Trial Authorization (CTA / IND)AN4035Ex-US Regulatory
Regulatory clearance in Australia to begin AN4035 Phase I trial
CEACAM5-enriched RAS-addicted solid tumorssource ↗
▲First Patient DosedAN9025Trial
First patient dosed in intermittent weekly dosing arm of Phase 1 trial of AN9025
advanced or metastatic solid tumors harboring RAS mutationssource ↗
▲Management ChangeCorporate
Appointment of Dr. David S. Hong and Dr. Piro Lito to Scientific Advisory Board
▲First Patient DosedAN9025Trial
First patient dosed in QW arm of AN9025 Phase I trial
advanced or metastatic solid tumors harboring RAS mutationssource ↗
▲Other Regulator MilestoneAN4035Ex-US Regulatory
HREC approval in Australia for Phase I trial of AN4035
CEACAM5-enriched, RAS-addicted solid tumorssource ↗
▲First Patient DosedAN9025Trial
First patient dosed in QD arm of AN9025 Phase I trial
advanced or metastatic solid tumors harboring RAS mutationssource ↗
Past FDA Catalysts and PDUFA Decisions
How ANL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | AN4005 | Phase 1a data readout | Phase 1a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
7
Drugs Scored
rNPV / MCap
Top Drug
Top 26%
Micro Cap(rank 176 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AN8025 Small moleculeNCT07639047 | Advanced Solid Tumor | Phase 1 | RECRUITING | 91 | Jan 1, 2028 | ||||||
| AN4035 Small moleculeNCT07686445 | Solid Tumor (Phase I) | Phase 1 | RECRUITING | 228 | Dec 31, 2028 | ||||||
| AN4005 Small moleculeNCT04999384 | Advanced Solid Tumor | Phase 1 | RECRUITING | 31 | Dec 1, 2026 | ||||||
| AN9025 Small moleculeNCT07252479 | Solid Tumors | Phase 1 | RECRUITING | 118 | Jun 1, 2028 | ||||||
| Buparlisib & Paclitaxel Small moleculeCompletedNCT04338399 | Head and Neck Cancer | Phase 3 | COMPLETED | 487 | Nov 2, 2025 | ||||||
| Pelareorep Small moleculeCompletedNCT05519059 | Advanced or Metastatic Breast Cancer | Phase 1 | COMPLETED | 15 | May 30, 2023 | ||||||
| AN2025 Small moleculeCompletedNCT04975958 | Locally Advanced Solid Tumor | Phase 1 | COMPLETED | 47 | Jan 24, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ANL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ji PingDirector | Sell | -5,000 121,453 held | $15.95 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ANL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| VR Adviser, LLC | 1.1 % (37.5 %) | 36.95 M | 3.21 M |
Ownership Trends
ANL Short Interest
Shares sold short, counted twice a month.
9.54%
Short % of Float
of tradable shares sold short
5.1M
Shares Sold Short
+15.7% vs prior count
11.9 Very high
Days to Cover
trading days of normal volume to buy every short share back
426.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANL ranks across every disease it competes in
Competitive Position is a premium feature
See how ANL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANL News
-ANL
Oct 27, 2026Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
Adlai Nortye announced that its AN4035 program will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona. The presentation will cover translational and combination data from the ongoing Phase I study, highlighting AN4035's potential in targeting CEACAM5-expressing tumors. The event is scheduled for November 19, 2026.
Read more →-ANL
Oct 15, 2026▲ +11.1%on this news
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Adlai Nortye has announced a clinical collaboration with Lilly and Merck KGaA to evaluate AN4035, a pan-RAS(ON) inhibitor-based ADC, in combination with cetuximab. The ongoing global Phase I trial will assess the safety and efficacy of AN4035 in patients with CEACAM5-enriched, RAS-addicted solid tumors. Cetuximab will be supplied at no cost by both partners for trial sites in the U.S., Australia, and China.
Read more →-ANL
Sep 30, 2026Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
Adlai Nortye Group Ltd. has appointed Christopher Liu, PharmD, as the new Head of Investor Relations and Public Relations. Liu brings nearly a decade of experience in equity research, particularly in biotechnology and oncology. His expertise is expected to strengthen the company's engagement with investors and enhance communication regarding its developmental pipeline.
Read more →-ANL
Sep 8, 2026Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
Adlai Nortye has initiated a global Phase I trial for AN4035, a first-in-class ADC targeting CEACAM5 and armed with a pan-RAS(ON) inhibitor. The first patient has been dosed in Australia, and the U.S. FDA has cleared the IND application, allowing expansion into the U.S. The trial aims to evaluate the safety and efficacy of AN4035 in patients with RAS-addicted solid tumors.
Read more →-ANL
Aug 14, 2026Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Adlai Nortye Ltd. reported its first half 2026 financial results, highlighting ongoing enrollment in Phase I trials for its pan-RAS(ON) inhibitors AN9025 and AN4035. The company achieved its first regulatory approval for AN4035's trial and appointed two prominent oncologists to its advisory board. Financially, Adlai Nortye showed significant growth, with revenue rising to $13.1 million and a reduced net loss of $5.3 million.
Read more →-ANL
Aug 3, 2026Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
Adlai Nortye has received approval from Australia's HREC to begin a Phase I clinical trial for AN4035, a pan-RAS(ON) inhibitor ADC targeting CEACAM5. This trial aims to evaluate the drug's safety, tolerability, and efficacy in patients with specific solid tumors. The company is also preparing IND submissions to the FDA and NMPA.
Read more →-ANL
Jul 16, 2026▲ +6.8%on this news· ran to +22% by day 3
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
Adlai Nortye has announced the dosing of the first patient in the intermittent weekly dosing arm of its Phase 1 trial for AN9025, a pan-RAS(ON) inhibitor. This approach aims to widen the therapeutic window, potentially improving tolerability and efficacy. Both the QD and QW arms are currently enrolling patients, with initial data expected in early 2027.
Read more →-ANL
Jul 13, 2026▼ -6.4%on this newsshared move
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
Adlai Nortye Ltd. has expanded its Scientific Advisory Board by appointing Dr. David S. Hong and Dr. Piro Lito, both renowned oncologists. Their expertise in clinical development and RAS biology is expected to significantly influence the company's research and development strategies. This move underscores Adlai Nortye's commitment to advancing its innovative cancer therapies.
Read more →-ANL
Apr 16, 2026Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. has announced a private placement equity financing expected to raise approximately $150 million. The oversubscribed transaction involves participation from both new and existing institutional investors. The funds will support the development of the company's innovative cancer therapies, including RAS-targeting treatments. The private placement is set to close on April 17, 2026, pending customary conditions.
Read more →-ANL
Mar 3, 2026Adlai Nortye to Participate in Upcoming Investor Conferences
Adlai Nortye Ltd. announced its participation in two upcoming investor conferences: the Leerink Partners Global Healthcare Conference on March 10-11, 2026, and the Jefferies Global Healthcare Conference on June 3-4, 2026. The company is focused on developing innovative cancer therapies, including next-generation immunotherapies and RAS-targeting therapies. This engagement is expected to strengthen its visibility in the investment community.
Read more →-ANL
Feb 12, 2026Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
Adlai Nortye has initiated a Phase 1 clinical trial for AN9025, a pan-RAS inhibitor, with the first patient dosed in the U.S. This trial aims to assess the safety and efficacy of AN9025 in patients with solid tumors harboring RAS mutations. The study is part of a multi-regional collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd.
Read more →-ANL
Feb 3, 2026Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. has announced a successful private placement equity financing, raising approximately $140 million. The financing involves the sale of Class A ordinary shares, co-led by Cormorant Asset Management and Columbia Threadneedle Investments. The funds will support the development of the company's innovative cancer therapies, particularly in RAS-targeting and next-generation immunotherapies.
Read more →-ANL
Dec 29, 2025▲ +9.8%on this news
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
Adlai Nortye has entered an exclusive licensing agreement with ASK Pharm for its pan-RAS (ON) inhibitor AN9025, granting ASK rights to develop and commercialize the drug in Greater China. The deal includes potential earnings of up to RMB 1.6 billion, with an upfront payment and milestone payments. This collaboration aims to accelerate the development of AN9025, which has shown promise in preclinical studies against RAS-mutant cancers.
Read more →-ANL
Oct 22, 2025ADLAI NORTYE LTD. c/o PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands NOTICE OF 2025 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on
Adlai Nortye Ltd. has announced its extraordinary general meeting scheduled for December 1, 2025. Shareholders will be voting on several key proposals including a change of the company's domicile from the Cayman Islands to Singapore. The proposals also involve adopting a new charter and a change of the company's name. Shareholders of record as of October 30, 2025, will be eligible to participate in the voting process.
Read more →-ANL
Aug 8, 2024Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress - Company Announces Appointment of Roger Sawhney, M.D. as a New Member of the Board of Directors SINGAPORE and N
Adlai Nortye Ltd. reported its first half 2024 financial results, showcasing progress in its clinical pipeline and operational improvements. The company appointed Roger Sawhney, M.D. to its Board of Directors and shared promising data from its ongoing trials. Net loss for the period decreased significantly from the previous year, yet cash usage in operations remains a concern. The company is focused on the advancement of its lead candidate, buparlisib, with Phase 3 data expected in early 2025.
Read more →-ANL
May 23, 2024▼ -5.6%on this news· ran to -35% by day 3
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 SINGAPORE and NORTH BRUNSWICK, N.J. and
Adlai Nortye Ltd. announced it will present findings on the combination of AN0025 and definitive chemoradiotherapy (dCRT) for treating unresectable locally advanced esophageal cancer at the ASCO 2024 meeting. The data highlights the potential efficacy observed in a previous clinical trial. AN0025, which acts as a selective EP4 inhibitor, may enhance treatment outcomes when combined with current chemotherapy techniques. The company continues to emphasize its commitment to innovative cancer therapies and global partnerships for advancing oncology research.
Read more →-ANL
Apr 2, 2024Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29 th , 2024 -- Adlai Nortye Ltd. (NASDAQ: ANL) (the "Company" or
Adlai Nortye Ltd. has announced the appointment of Dr. Archie Tse as the new Head of Research & Development. Dr. Tse, with an extensive background in oncology, previously held senior roles at CStone Pharmaceuticals, Merck, and Daiichi-Sankyo. His leadership is anticipated to strengthen the company's focus on developing innovative cancer therapies. Adlai Nortye aims to leverage Dr. Tse's expertise to enhance its R&D efforts and advance its pipeline of drug candidates.
Read more →About Adlai Nortye Ltd. American Depositary Shares
BIOPHARMAWATCH ELITE PLUS
Trade the next ANL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime